Azacitidine

Catalog No.S1782 Synonyms: NSC 102816

Azacitidine  Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • R-2HG treatment or chemotherapeutic treatment, especially their combinations, decrease MYC levels in leukemic cells (using MONOMAC-6 as a representative). AZA:Azacitidine.

    Cell, 2018, 172(1-2):90-105. Azacitidine purchased from Selleck.

    Cells were treated with 50 µM AZA and 2 different concentrations of each HDACi for 72 h before cell viability was determined. Data is represented as percent in comparison to vehicle (DMSO) treated cells (set to 100%).

    Epigenetics, 2015, 10(5): 431-45. Azacitidine purchased from Selleck.

  • (A) The graph shows percentage of human CD45+ leukemic cells in mouse blood. At time 0, mice were injected with MV4;11 cells. The arrow indicates when drug treatment began. (B) Kaplan-Meier plot shows the percentage of mice surviving following treatment. The p-value for median survival between different treatment groups (by ANOVA) is<0.0001. The mice treated with the combination of azacitidine and panobinostat were disease-free until they were sacrificed 18 months post cell injection.

    Leuk Res, 2017, 58:91-97. Azacitidine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  M1e1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvIZpYxNjFvNUCg{txO MXGxNk04OiCq M33KPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NWnobnl4OjZzM{OyOFY>
Jurkat  M3;pNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLVeHZkOC5zLUWwJO69VQ>? NHfYTIYyOi15MjDo MkHPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3L0RlI3OTN|MkS2
CA46 MXXGeY5kfGmxbjDBd5NigQ>? MX6yNOKhyrWP MknnOFghcA>? MoDxbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w M4HIVFI3OTN|MkS2
Raji  NX2wWFRjTnWwY4Tpc44hSXO|YYm= M3\RS|E2yqEEtV2= M3fJWVQ5KGh? NVPuO29ScW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO|aX;u NVT0c2Z1OjZzM{OyOFY>
Jurkat  NIHndYRHfW6ldHnvckBCe3OjeR?= Ml7KN{42yqEEtV2= M4XMe|Q5KGh? MWPpcoNz\WG|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25? MlXrNlYyOzN{NE[=
MDA-MB-231 NWfPfJV6TnWwY4Tpc44hSXO|YYm= M1;KflEwOi53L{Wg{txO MX20PEBp NV;tXZlN\GWlcnXhd4V{KHSqZTDQWHBPOTJiZYjwdoV{e2mxbjDheEB1cGViY3;uZ4VzdnS{YYTpc44hd2ZiNdMg{txOKDR6wrDo NEHIbY4zPThzN{KyPS=>
MDA-MB-231 NIGzc4lHfW6ldHnvckBCe3OjeR?= MmXlNU8zNjVxNTFOwG0> MXK0PEBp MW\pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCHLXPh[IhmemmwIH3SUmEh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFIvPcLizszN[o9zKDR6wrDo MXGyOVgyPzJ{OR?=
MDA-MB-231 M{LrZ2Z2dmO2aX;uJGF{e2G7 MXKxM|IvPS93IN88US=> Mkn5NlQwPDhiaB?= NYjtSnB{cW6mdXPld{Ahe2mpbnnmbYNidnRiUFHSVEBkdGWjdnHn[UBi\nSncjC0PEBp Ml3wNlU5OTd{Mkm=
MCF-7 NWHxNZNUTnWwY4Tpc44hSXO|YYm= NHnvdFQyNzJwNT:1JO69VQ>? MVWyOE81QCCq MVPpcoNz\WG|ZYOgVGFTWCClbHXheoFo\cLi MkDONlU5OTd{Mkm=
MDA-MB-231  M4L2eWZ2dmO2aX;uJGF{e2G7 M3npTlEwOi53L{Wg{txO NYfCW3gzOjRxNEigbC=> NHHJ[WlqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhdWmUTlGtNVI1KGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2KM7:TR?= MUeyOVgyPzJ{OR?=
A498 NWj0OFk3TnWwY4Tpc44hSXO|YYm= NWS2cVFlOTBiwsXN MnfaO|IhcA>? NFGyWpNqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> NWLGcYJsOjV3NkmwPFY>
CaKI-2 NX32UZI{TnWwY4Tpc44hSXO|YYm= NWPadHk5OTBiwsXN MmnkO|IhcA>? NYDLNWRScW6mdXPld{B1cGViQVTBUXRUOThiZ3Xu[UBmgHC{ZYPzbY9v M2LLSlI2PTZ7MEi2
Ketr-3 MUjGeY5kfGmxbjDBd5NigQ>? NX3FSVBHOTBiwsXN M2XUfVczKGh? MlrVbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u MoWyNlU2PjlyOE[=
A253 NGLUVJRHfW6ldHnvckBCe3OjeR?= Ml7yNVAhyrWP NEP2fVYxNTRiZB?= M1K0WIlv[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsJI9nKHSqZTDNN3LDqGGodHXyJFI1KGh? NGDvd4ozPTR6NUWzOi=>
A253 MUHGeY5kfGmxbjDBd5NigQ>? MXyxNEDDvU1? M3TlOlczKGh? M2fhS4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjD0bIUhVTOUIHnuJIJwfGhibXXtZpJidmViYX7kJIN6fG:|b3zpZ{BxemWyYYLheIlwdnN? MmnnNlU1QDV3M{[=
A253 MVrGeY5kfGmxbjDBd5NigQ>? MlXLNVAhyrWP MUOwMVQh\A>? M2HtWJJm\HWlZYOgeIhmKDVvbXX0bJlt[3m2b4PpcoUh[2:wdHXueC=> Mn;jNlU1QDV3M{[=
PC3 NV3Zco5GTnWwY4Tpc44hSXO|YYm= MWKwMlIh|ryPwrC= MX[0JIQ> MXLpcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 NHHqbXczPTR5N{O0NC=>
MCF7 MYDGeY5kfGmxbjDBd5NigQ>? NFTKbJUxNjNizszNxsA> MVu0JIQ> M1e5[olv[3KnYYPld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyxiU1\SVFEh[W6mIGPMR|ZCOTViY3;tZolv\WRid3n0bEBIW0tzMk[= NVjOUZBIOjV2N{ezOFA>
PC3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPhbpB3OC5{IN88UeKh NV3lWJc2PCCm M4DEd4Rm[3KnYYPld{B1cGViY3XscEBoem:5dHigeI8hOjBwMzWgZ49u[mmwZXSge4l1cCCJU1uxNlY> MXyyOVQ4PzN2MB?=
MCF7 NG\sRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7uSXJ6OC5|IN88UeKh NUC2dWU3PCCm NUXtc21N\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEAzPC56JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> NH71ZYozPTR5N{O0NC=>
BGC-823 MoDaSpVv[3Srb36gRZN{[Xl? M4\MdVXDqM7:TR?= MVm3NkBp MYTk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 MoT0NlU1PzV5M{O=
MKN28 NGTRWVJHfW6ldHnvckBCe3OjeR?= NHS4blg2yqEQvF2= MYi3NkBp NEH5WXdl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 M1;uc|I2PDd3N{Oz
SGC-7901 MV3GeY5kfGmxbjDBd5NigQ>? NIDIUI42yqEQvF2= Ml;CO|IhcA>? MVXk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 M3rFWFI2PDd3N{Oz
MKN45 NYLSUoFWTnWwY4Tpc44hSXO|YYm= MlLkOeKh|ryP NHyzfYY4OiCq NFS5UIhl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 Moe0NlU1PzV5M{O=
BGC-823 NYXCUnJDTnWwY4Tpc44hSXO|YYm= MX61xsDPxE1? MXW3NkBp M3LiN4Rm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm= NXvsTmtuOjV2N{W3N|M>
MKN28 NVyxc45FTnWwY4Tpc44hSXO|YYm= NX7XR5dwPcLizszN NH3uXHc4OiCq NGfKcHZl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDQVmwuOyC|aXfubYZq[2GwdHz5 NH7VPIszPTR5NUezNy=>
SGC-7901 MYXGeY5kfGmxbjDBd5NigQ>? MVi1xsDPxE1? MonqO|IhcA>? NYXyZ2E{\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> MlrFNlU1PzV5M{O=
MKN45 NWXHe4x3TnWwY4Tpc44hSXO|YYm= MYK1xsDPxE1? M1PxTlczKGh? MVrk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 NFTtcYYzPTR5NUezNy=>
HREC NYq0e3NrTnWwY4Tpc44hSXO|YYm= MW[1M|ExyqEQvF2= MXe0PEBp MXHpcoR2[2W|IGDFSGYhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGjSeoozPTN3Mke0Oy=>
HRPE M2rwe2Z2dmO2aX;uJGF{e2G7 M{TBelUwOTEEoN88US=> MkjGOFghcA>? NVv4eYp2cW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWCyOVM2Ojd2Nx?=
HREC NF:0[41HfW6ldHnvckBCe3OjeR?= Mn\sOU8yOMLizszN M4XGfFQ5KGh? MXTkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLQ1HNMVEhMG6xdDDwdo91\WmwIHzleoVtKGmwIFjSVGUh[2WubIOpMEBKVC1zzsKg[I9{\S2mZYDlcoRmdnSueR?= Ml7rNlU{PTJ5NEe=
HRPE M1PxUmZ2dmO2aX;uJGF{e2G7 M2HBfVUwOTEEoN88US=> NYrwfYV3PDhiaB?= NXradGRv\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWwuOc7{LDDhcoQhVU2SMjDkc5NmNWSncHXu[IVvfGy7 NV3TWIhWOjV|NUK3OFc>
MSCs NULlSGJGTnWwY4Tpc44hSXO|YYm= MWqxNEDPxE1? NUT4TVViOjRiaB?= MY\wdo9ud3SnczD0bIUh[2:vbXn0cYVvfCCxZjDNV2N{KHSxIH35c4NiemSrYXyg[Iln\mW{ZX70bYF1cW:w NU\wVI1TOjV|NUGzPVU>
HL-60 NV7QSW85TnWwY4Tpc44hSXO|YYm= NFXvWIQ2KM7:TR?= MnXsO|IhcA>? NILj[lJFVVOR M120N5Nq\26rZnnjZY51dHlidYDy[Yd2dGG2ZYOgXm5HOzh{IHX4dJJme3Orb36= NXG0WVE{OjV|MUmwOFk>
MV4-11 M4nucWZ2dmO2aX;uJGF{e2G7 NFW1PGg2KM7:TR?= MVW3NkBp Mki0SG1UVw>? NHX6d45{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO|aX;u M{P6V|I2OzF7MES5
A2780 MUjGeY5kfGmxbjDBd5NigQ>? M{XRTFUhyrWPwrC= NYPVbpFIPyCm NYPkd|RWcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= MVqyOVI6QTZ7NB?=
CP70 NWDkS4JlTnWwY4Tpc44hSXO|YYm= MXq1JOK2VcLi Mn7OO{Bl NXH3R4cycW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= MlPRNlUzQTl4OUS=
A2780 M2PFdWZ2dmO2aX;uJGF{e2G7 M2nmdVUhyrWPwrC= M1XSN|ch\A>? Mne5e4Vic2WwczD0bIUhdGW4ZXygc4YhdWW2aInsZZRqd25? NYfo[451OjV{OUm2PVQ>
CP70 Ml\ySpVv[3Srb36gRZN{[Xl? MlLGOUDDvU4EoB?= NWn6N|F6PyCm M4npUJdm[WunboOgeIhmKGyndnXsJI9nKG2ndHj5cIF1cW:w NXrRZVZuOjV{OUm2PVQ>
OCM3 M4LZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKwMlUwOS9{IN88US=> M3\tfVch\A>? NFqyVYJFVVOR NX;QdZBDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWDEcJRqOjVzNE[5PFE>
92.1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzUTGtqOC53L{GvNkDPxE1? M1LnSFch\A>? NFnRZYxFVVOR NWm3V3RScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWHxOFNUOjVzNE[5PFE>
OCM1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPtNE42NzFxMjFOwG0> MWC3JIQ> M4HC[GROW09? MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MUSyOVE1Pjl6MR?=
OMM1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHxZXYxNjVxMT:yJO69VQ>? MVi3JIQ> NU\xdY9DTE2VTx?= NITPPFRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1H3[FI2OTR4OUix
Mel 285 NX\qNGtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTOcnMzOC53L{GvNkDPxE1? M1q5cVch\A>? MX7EUXNQ MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MY[yOVE1Pjl6MR?=
Mel 290 NHrwOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SyPVAvPS9zL{Kg{txO NYPRW21DPyCm MXPEUXNQ Mnn6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MofWNlUyPDZ7OEG=
OCM3 MmfnSpVv[3Srb36gRZN{[Xl? MkPmNE42NzFizszN MUe0PEBp NVXLfYZuTE2VTx?= M4LSNoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? NEDJR5YzPTF2Nkm4NS=>
92.1 MlS0SpVv[3Srb36gRZN{[Xl? Mlf5NE42NzFizszN Mom2OFghcA>? NWL6VHpTTE2VTx?= Mnn1[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NUS1V2tUOjVzNE[5PFE>
OCM1 NFrEdnpHfW6ldHnvckBCe3OjeR?= MX2wMlUwOSEQvF2= NGS4T2o1QCCq MlWxSG1UVw>? MYrk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 MXGyOVE1Pjl6MR?=
OMM1 MoTESpVv[3Srb36gRZN{[Xl? NFHDV5gxNjVxMTFOwG0> MXq0PEBp M2Lpb2ROW09? MlrB[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? M3\GNFI2OTR4OUix
Mel 285 NVT0V3ZRTnWwY4Tpc44hSXO|YYm= NWCzOJZmOC53L{Gg{txO NFPpfmg1QCCq NGSwV41FVVOR NGjqTJhl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 MU[yOVE1Pjl6MR?=
Mel 290 M1XoVmZ2dmO2aX;uJGF{e2G7 NV7NdYVtOC53L{Gg{txO MoXCOFghcA>? NXzxfGlUTE2VTx?= MmrV[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MlvkNlUyPDZ7OEG=
OCM3 MWHGeY5kfGmxbjDBd5NigQ>? NWLWe4E1OC53L{Gg{txO NGT4c4U1QCCq MknrSG1UVw>? NF34VHNl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh MXWyOVE1Pjl6MR?=
Mel 290 NWDqVoZ3TnWwY4Tpc44hSXO|YYm= NXzEU|B3OC53L{Gg{txO MUm0PEBp MljLSG1UVw>? Mmex[IVkemWjc3XzJIlvfmG|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=> NF3SOpIzPTF2Nkm4NS=>
OMM1 MVHGeY5kfGmxbjDBd5NigQ>? NHnhU|cxNjVxMTFOwG0> NHPFN4I1QCCq NH3lc4ZFVVOR Mn7B[IVkemWjc3XzJIlvfmG|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=> NFO5XGgzPTF2Nkm4NS=>
OCM1 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX;mSHRZOC53L{Gg{txO MWe1JIQ> MYHEUXNQ MW\k[YNz\WG|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?= NGH3eGQzPTF2Nkm4NS=>
92.1 NGPPc45E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{H4ZlAvPS9zIN88US=> MVi1JIQ> M2nkSWROW09? NH3GcoNl\WO{ZXHz[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgbY5pcWKrdHnvci=> Mo\ONlUyPDZ7OEG=
OCM1 MVnGeY5kfGmxbjDBd5NigQ>? M4qx[FAvPS9zIN88US=> NFKwPWw1QCCq NH7JWplFVVOR M3fuc4NifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= M1HGclI2OTR4OUix
OCM3 MlX1SpVv[3Srb36gRZN{[Xl? NGDTNFYxNjVxMTFOwG0> NVuwTYlqPDhiaB?= M4HTd2ROW09? NFvQfVRk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp MVmyOVE1Pjl6MR?=
92.1 MkH4SpVv[3Srb36gRZN{[Xl? NH;CUWkxNjVxMTFOwG0> MUK0PEBp NWPqWmJQTE2VTx?= MkDWZ4F2e2W|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?= NH:yNXMzPTF2Nkm4NS=>
IMR32 NGrUSo9HfW6ldHnvckBCe3OjeR?= M2PkN|Mh|ryP MYS3NkBp MX;EUXNQ NYrzUI9rcW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 M{ewXFI2OTB2OEWw
IMR5-75 M3vsV2Z2dmO2aX;uJGF{e2G7 MV6zJO69VQ>? MknTO|IhcA>? M{jvWWROW09? M2\Hd4lv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> NXLCXFlMOjVzMES4OVA>
Be(2)-C MXjGeY5kfGmxbjDBd5NigQ>? NVHWO2xPOyEQvF2= NUS2VpluPzJiaB?= MnLTSG1UVw>? NV3JempjcW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 NGe4bGUzPTFyNEi1NC=>
Bxpc-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjGbFZTPS9zMDFOwG0> NHe3dngzPC92OD:3NkBp NG\YepdqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCEeIDjMVMh[2WubIOgbY4hfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6ncoO= MVuyOVA3OTd|MR?=
Bxpc-3 NVrBVVJLSXCxcITvd4l{KEG|c3H5 MUm1M|ExKM7:TR?= NGD2XlQzPC92OD:3NkBp NHvTN2lqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=> MlLGNlUxPjF5M{G=
Bxpc-3 NEDUOYhHfW6ldHnvckBCe3OjeR?= M4[2SlUwOTBizszN M3yyXlI1NzR6L{eyJIg> MlrU[IVkemWjc3XzJO6zNWOjdHXubY4h\XiycnXzd4lwdiCjZoTldkAzPCCq NWO0VYs{OjVyNkG3N|E>
Bxpc-3 M2XPWWZ2dmO2aX;uJGF{e2G7 MYG1M|ExKM7:TR?= MWGyOE81QC95MjDo NGrVcFVl\WO{ZXHz[ZMh[3mlbHnuSFEh\XiycnXzd4lwdiCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOTBizszN NVTWSFVKOjVyNkG3N|E>
Bxpc-3 NUTv[|Z7TnWwY4Tpc44hSXO|YYm= NWj5No9wPS9zMDFOwG0> MU[yOE81QC95MjDo MmfE[I94di2{ZXf1cIF1\VNiYz3tfYMhdVKQQTDlfJBz\XO|aX;uJIlvKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYLz NF7EflIzPTB4MUezNS=>
HL-60 NHm0NolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxMlAh|ryP MlHmOFghcA>? NXux[|Z6e2mpbnnmbYNidnSueTDpcohq[mm2czDIUE03OCClZXzsJIdzd3e2aNMg MYeyOVA2OTFzOR?=
HL-60 NWXFdFZKTnWwY4Tpc44hSXO|YYm= Mkj0NU4xKM7:TR?= NVvqVIdpPDhiaB?= NXq2fWFZcW6lcnXhd4V{KHB{MWfBSlEwS0mSMdMgZY5lKGOjc4Dhd4UuOyCneIDy[ZN{cW:wwrC= MYGyOVA2OTFzOR?=
HL-60 NXe4[JV[TnWwY4Tpc44hSXO|YYm= MnvQNU4xKM7:TR?= MVe0PEBp NEfEZ5dl\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= NVzSTW5sOjVyNUGxNVk>
HuTu-80  MVTGeY5kfGmxbjDBd5NigQ>? MXWxM|UwOTBizszN Mo\LOFgwPzJiaB?= NHf6RWdqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhcHWvYX6gUnBEOUxzIH3SUmEhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYCyOFkxPDB4Mh?=
Caco2  MkHDSpVv[3Srb36gRZN{[Xl? MXWxNEDPxE1? NU[zbmZFPDhiaB?= MkfQbY5kemWjc3XzJG5RSzGOMTDlfJBz\XO|aX;u M2KwPVI1QTB2ME[y
HepG2  NGL3cGNHfW6ldHnvckBCe3OjeR?= MUKwMVI2KM7:TR?= NVLxb2tSOjRiaB?= NXnQemRp\GWlcnXhd4V{KHO3YoTpcIl{cW5xa3X4bY4hfHmyZTC5JEhRS1ONOTmgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgQ>? Ml3oNlQ5PTV4NE[=
HepG2  MVLGeY5kfGmxbjDBd5NigQ>? MV[wMVI2KM7:TR?= NYewd4FjOjRiaB?= MUfpcoNz\WG|ZYOgcI94KGSnboPpeJkhdGmyb4Dyc5RmcW5icnXj[ZB1d3JiKFzEUHIqKGenbnWg[ZhxemW|c3nvcuKh NYf2eI5SOjR6NUW2OFY>
HepG2  MlfwSpVv[3Srb36gRZN{[Xl? M13HelExKM7:bdMg NXLZfWdJOC1{NDDo NWrjRVI2\GWlcnXhd4V{yqCSQ2PLPeKh[W6mwrDIUWdEWsLiZYjwdoV{e2mxbjDhcoQhcW6lcnXhd4V{KEyGTGKg[ZhxemW|c3nvckBi\nSncjC2JIg> M1[3UlI1QDV3NkS2
HepG2  NH\aWIpHfW6ldHnvckBCe3OjeR?= MmjuNVAh|ryv MVuyOEBp NVHSRVRCeHKxbX;0[ZMh[3m2b4PvcIlkKG6ndYTyZYwhdGmyaXSgZYNkfW23bHH0bY9vKGmwZHXw[Y5l\W62bImgc4Yh\XixZ3Xuc5V{KGyrcH;wdo91\Wmwcx?= MX2yOFg2PTZ2Nh?=
HepG2  NUS5W2ZKTnWwY4Tpc44hSXO|YYm= MV6xNEDPxG1? NH;ZSVEzPCCq NHO3NGNxemW4ZX70d{BUWkWEUDDwdo9k\XO|aX7n NH\jdlIzPDh3NU[0Oi=>
HC45  NUDDdHh7TnWwY4Tpc44hSXO|YYm= NYL5VVNTPcL3TdMg Ml7OOEBl MmCzdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? MUSyOFc3OjhyOR?=
CNDT2  MmXLSpVv[3Srb36gRZN{[Xl? Ml\OOeK2VcLi NHfvTpg1KGR? MkTXdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? NIHlfXMzPDd4MkiwPS=>
CNDT2  M4\uNWZ2dmO2aX;uJGF{e2G7 Mkj3OeK2VcLi Mn3oOEBl NVfuXnNGcW6lcnXhd4V{KGenbnWg[ZhxemW|c3nvckBw\sLiV1nGNUwhWDF4LDDDSGgyNMLiTFHNRVEtyqCjbnVCpGNVVk6EMR?= MUKyOFc3OjhyOR?=
T-cells MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHVSlNFPS9{MDFOwG0> NYTKeHhyOC12ODDo MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NFzxdmkzPDd3N{K4Ny=>
CD3+ T-cells M2PvWmZ2dmO2aX;uJGF{e2G7 Mnf6OU8zOCEQvF2= NXLidGdOPDhiaB?= MnzVeZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= NY\MSGpMOjR5NUeyPFM>
CD4+ T-cells NFOyXmVHfW6ldHnvckBCe3OjeR?= MlzEOU8zOCEQvF2= NFu4TGk1QCCq MU\1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= MmPwNlQ4PTd{OEO=
CD8+ T-cells NFr4PWtHfW6ldHnvckBCe3OjeR?= MnXTOU8zOCEQvF2= Mni0OFghcA>? MVH1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= NHH3cIIzPDd3N{K4Ny=>
CD3+ T-cells NWjJflI2TnWwY4Tpc44hSXO|YYm= MYO1M|IxKM7:TR?= NUjxTnc4PDhiaB?= M2LRVZVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKE[RWGCz MnvzNlQ4PTd{OEO=
CD4+ T-cells MV7GeY5kfGmxbjDBd5NigQ>? MWG1M|IxKM7:TR?= NHf1OW41QCCq NWLrSoNpfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM> M3SxcVI1PzV5Mkiz
CD4+ T-cells NYTBS2k4TnWwY4Tpc44hSXO|YYm= MVm1M|IxKM7:TR?= NIfIcoE1QCCq M132dJJm\HWlZYOgWGJGXDIEoH3SUmEh\XiycnXzd4lwdg>? MV6yOFc2PzJ6Mx?=
CD4+ T-cells NH7oS5BHfW6ldHnvckBCe3OjeR?= M3TiZlUwOjBizszN NXrpNFgzPDhiaB?= MoPKeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4bDqFKRUt8zeOKh Mo\CNlQ4PTd{OEO=
CD4+ T-cells M2DhOGZ2dmO2aX;uJGF{e2G7 NEj0PGY2NzJyIN88US=> NFi3O5M1QCCq Mom2bY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? NYjtNpE5OjR5NUeyPFM>
CD8+ T-cells M{DqfGZ2dmO2aX;uJGF{e2G7 M2rYblUwOjBizszN MXG0PEBp NXq2UFJGcW6qaXLpeJMhdWWvb4L5JHQu[2WubIO= MnvGNlQ4PTd{OEO=
CD3+ T-cells NYPFdFN4TnWwY4Tpc44hSXO|YYm= NGjofYU2KM7:TR?= NFLReWI1QCCq NXjyVHZvemWmdXPld{Btd26pLYTldo0hdWWvb4L5JINmdGxicHjlco91gXCn NVW4V2h5OjR5NUeyPFM>
U937 NHXORotCeG:ydH;zbZMhSXO|YYm= M2\KUVExKM7:TR?= MVK3NkBp MnH1bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NXu3WJFHOjR4OEC4OlU>
HL-60 Ml7uRZBweHSxc3nzJGF{e2G7 MUOxNEDPxE1? NGnBVVQ4OiCq NXXwdJBncW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MWeyOFY5ODh4NR?=
MCF7 MkfySpVv[3Srb36gRZN{[Xl? NWHTcGp2PSEQvF2= NWn1WnlEPDhiaNMg NF7wNFVlcXOybHH5d{B{\WynY4TpeoUhfG:6aXPpeJkhfG:5YYLkJJN2e3CnbnTl[EBOS0ZvNzDj[Yxtew>? MYWyOFY{OzN3MB?=
MCF7 NXvDeHZsTnWwY4Tpc44hSXO|YYm= NHnjd3cyOCEQvF2= NUnCfHI{OjRiaNMg M1zDd4lv\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2ViNzDhcoQhWEGUUNMg MYmyOFY{OzN3MB?=
MCF7 NYPwZZlWTnWwY4Tpc44hSXO|YYm= NF;oeZIx6oDVMD61JO69VcLi NVKwcXppPyCm MUjpcohq[mm2czD0bIUh\3Kxd4ToJG1ETi15IIT1cY9ze3CqZYLld{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW|wrC= M4\mTFI1PjN|M{Ww
MCF7 NUDwSFFjTnWwY4Tpc44hSXO|YYm= NU\qdHNzOC53IN88UeKh M2\NbVE1KGR? NFnYe2Fz\WS3Y3XzJJRp\SC|aYrlJI9nKE2FRj23JINwdG:waXXzJIVu[mWmZHXkJIlvKHOxZoSgZYdieg>? NU\ocHBXOjR4M{OzOVA>
MCF7 MWjGeY5kfGmxbjDBd5NigQ>? NHzwT|kxNjB34pETNlAh|ryP NXK1OXpMOSCm NWW1dVJuemWmdXPld{B1cGViY3zvcoFtKHO3co\peoFtKG:oIF3DSk04KGOnbHzzJIlvKG2xbn;sZZlmeiCldXz0eZJmew>? MVmyOFY{OzN3MB?=
T47D  NWjp[5BrTnWwY4Tpc44hSXO|YYm= MYSwMlUh|ryP MXi0JIQ> NEnxN|hqdmirYnn0d{B1fW2xcoPwbIVz\SCob4LtZZRqd25? MVSyOFY{OzN3MB?=
MCF7 Mmi4SpVv[3Srb36gRZN{[Xl? NILRdFIxNjYkgKOxNEDPxE1? M4XDWFQ5KGkEoB?= NVPvXG04cW6qaXLpeJMhfGinIHfhdEBkdG:|dYLlJIlvKHSqZTD3c5Vv\CCqZXHsbY5oKGG|c3H5 MW[yOFY{OzN3MB?=
MCF7 MlXYSpVv[3Srb36gRZN{[Xl? NWfkdo9qOC9zMDFOwG0> M3TBNlI1KGh? M3vJRolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXA6 M1rkZVI1PjN|M{Ww
MDA-MB-231  MW\GeY5kfGmxbjDBd5NigQ>? NHLu[3oxNjYkgKOxNEDPxE1? NEH2ZnU{PiCq M4rRVYlvcGmkaYTzJJRp\SCvaXfyZZRqd25? M1PNelI1PjN|M{Ww

... Click to View More Cell Line Experimental Data

In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Formulation: Dissolved in 0.85% NaC1 solution immediately prior to use
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms NSC 102816

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02995655 Not yet recruiting Myelodysplastic Syndromes|Acute Myeloid Leukemia|AML|MDS Washington University School of Medicine|Cantex Pharmaceuticals February 28, 2017 Phase 1
NCT02750254 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia Washington University School of Medicine June 27, 2016 Phase 1|Phase 2
NCT02966782 Not yet recruiting Myelodysplastic Syndromes (MDS) AbbVie|Genentech, Inc. March 2017 Phase 1
NCT02959437 Not yet recruiting Advanced Solid Tumors Incyte Corporation February 2017 Phase 1|Phase 2
NCT02942758 Not yet recruiting Acute Myeloid Leukemia University Hospital Regensburg|Anticancer Fund, Belgium|Celgene February 2017 Phase 2
NCT03019003 Not yet recruiting Head and Neck Cancer Massachusetts General Hospital|AstraZeneca February 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine | Azacitidine supplier | purchase Azacitidine | Azacitidine cost | Azacitidine manufacturer | order Azacitidine | Azacitidine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID